Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of semaglutide injection versus 诺和泰® in adults with type 2 diabetes mellitus
CTR20260987Phase 3Active
- Sponsor
- Shanxi Jiayuan Biological Medicine
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Shanxi Jiayuan Biological Medicine. Started Mar 2026; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20260987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260987.